GlassScriptPhysician profile
Edmund Lee
NPI 1720049067
$6,062.74
in general payments reported to CMS, 2019-2025
14 companies · $17.33 in 2025
The $17.33 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,186 · 2020: $1,746 · 2021: $125 · 2022: $1,247 · 2023: $604 · 2024: $1,137 · 2025: $17.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.54 |
| Education | $262.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,933.85 | 2020-2024 | Bimzelx |
| Janssen Biotech, INC. | $1,291.79 | 2019-2024 | Tremfya, Simponi Aria, Simponi |
| Janssen Scientific Affairs, LLC | $741.06 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $346.12 | 2019-2025 | Duobrii, Siliq |
| Sun Pharmaceutical Industries INC. | $259.25 | 2019 | |
| Novo Nordisk INC | $137.92 | 2023 | Wegovy |
| Novartis Pharmaceuticals Corporation | $78.09 | 2022-2024 | |
| Abbvie INC. | $66.67 | 2023-2024 | |
| Endogastric Solutions, INC | $54.67 | 2024 | Esophyx |
| Incyte Corporation | $38.44 | 2023-2024 | Opzelura |
| Genzyme Corporation | $37.75 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $37.08 | 2023-2024 | Verquvo, Gardasil, Gardasil 9 |
| Regeneron Healthcare Solutions, INC. | $23.48 | 2024 | Dupixent |
| Esperion Therapeutics, INC. | $16.57 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmund Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.